Tes Pharma Will Use the elive™ Platform to Functionally Evaluate Response to TES-4207 in Live Tumor Fragments as a Monotherapy and in Combination With Immune Checkpoint Inhibitors
Need help?
Contact usTes Pharma Will Use the elive™ Platform to Functionally Evaluate Response to TES-4207 in Live Tumor Fragments as a Monotherapy and in Combination With Immune Checkpoint Inhibitors